Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

2019 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab​
Villalobos, M.; Czapiewski, P.; Reinmuth, N.; Fischer, J.; Andreas, S. ; Kortsik, C. & Serke, M. et al.​ (2019) 
Oncology Letters,.​ DOI: https://doi.org/10.3892/ol.2019.10153 

Documents & Media

License

GRO License GRO License

Details

Authors
Villalobos, Matthias; Czapiewski, Piotr; Reinmuth, Niels; Fischer, Jürgen; Andreas, Stefan ; Kortsik, Cornelius; Serke, Monika; Wolf, Martin; Neuser, Petra; Reuss, Alexander; Schnabel, Philipp; Thomas, Michael 
Issue Date
2019
Journal
Oncology Letters 
ISSN
1792-1074
eISSN
1792-1082

Reference

Citations


Social Media